Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Naporafenib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Erasca To Present SEACRAFT-1 Phase 1 Data At EORTC Symposium
    Erasca To Present SEACRAFT-1 Phase 1 Data At EORTC Symposium

    25 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/25/2952906/0/en/Erasca-to-Present-Preliminary-SEACRAFT-1-Phase-1-Data-for-Naporafenib-Plus-Trametinib-in-RAS-Q61X-Mutant-Solid-Tumors-as-Oral-Presentation-at-36th-EORTC-NCI-AACR-Symposium.html

    GLOBENEWSWIRE
    25 Sep 2024
    Share Share
    Erasca Reports Second Quarter 2024 Business Updates and Financial Results
    Erasca Reports Second Quarter 2024 Business Updates and Financial Results

    12 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/12/2928728/0/en/Erasca-Reports-Second-Quarter-2024-Business-Updates-and-Financial-Results.html

    GLOBENEWSWIRE
    12 Aug 2024
    Share Share
    Erasca Initiates SEACRAFT-2 Phase 3 Trial For Naporafenib InMutant Melanoma
    Erasca Initiates SEACRAFT-2 Phase 3 Trial For Naporafenib InMutant Melanoma

    18 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/18/2900371/0/en/Erasca-Initiates-SEACRAFT-2-Pivotal-Phase-3-Trial-Evaluating-Naporafenib-Plus-Trametinib-in-Patients-with-NRAS-Mutant-Melanoma.html

    GLOBENEWSWIRE
    18 Jun 2024
    Share Share
    Erasca Reports Fourth Quarter 2023 and Full Year 2023 Financial Results
    Erasca Reports Fourth Quarter 2023 and Full Year 2023 Financial Results

    27 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/27/2853585/0/en/Erasca-Reports-Fourth-Quarter-2023-and-Full-Year-2023-Business-Updates-and-Financial-Results.html

    GLOBENEWSWIRE
    27 Mar 2024
    Share Share
    Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib
    Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib

    11 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/11/2793788/0/en/Erasca-Granted-FDA-Fast-Track-Designation-for-Pan-RAF-Inhibitor-Naporafenib-in-Patients-with-Advanced-NRAS-Mutated-Melanoma.html

    GLOBENEWSWIRE
    11 Dec 2023
    Share Share
    Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs
    Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs

    28 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/28/2786879/0/en/Erasca-Achieves-Key-Milestones-for-Naporafenib-and-ERAS-801-Programs-and-Extends-Cash-Runway.html

    GLOBENEWSWIRE
    28 Nov 2023
    Share Share